Earningsreported sales revenue of 2,775 million euros in FY2023, a significant drop of 20.7% year-over-year in constant currency, signaling potential financial challenges.
Inventory ManagementInventory destocking expected to normalize, with current Pharma RM inventory levels estimated to be 3-5% above the pre-COVID average, potentially affecting cash flow and cost management.
Market PerformanceChina market remained weak, with management highlighting a slower consumption rate which could impact future revenue streams and market share.